Home » Stocks » CTIC

CTI BioPharma Corp. (CTIC)

Stock Price: $3.27 USD 0.15 (4.81%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $3.24 -0.03 (-0.92%) Jan 21, 5:35 PM
Market Cap 244.53M
Revenue (ttm) n/a
Net Income (ttm) -45.64M
Shares Out 73.71M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $3.27
Previous Close $3.12
Change ($) 0.15
Change (%) 4.81%
Day's Open 3.14
Day's Range 3.10 - 3.29
Day's Volume 515,999
52-Week Range 0.69 - 3.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 3 weeks ago

Innovation paid off big for investors.

Other stocks mentioned: AQB, IBIO, ALPN
PRNewsWire - 1 month ago

SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. ...

Seeking Alpha - 1 month ago

CTIC recently received FDA's accelerated approval go-ahead for pacritinib in MF patients with severe thrombocytopenia. This considerably reduces the risks associated with the company.

PRNewsWire - 1 month ago

SEATTLE, Dec. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in the prevention of acute...

PRNewsWire - 1 month ago

SEATTLE, Nov. 30, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Det...

Seeking Alpha - 2 months ago

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disea...

PRNewsWire - 2 months ago

SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, No...

InvestorPlace - 3 months ago

CTI BioPharma (CTIC) news for Wednesday includes plans to submit a new drug application (NDA) sending CTIC stock soaring higher. The post CTI BioPharma News: Why CTIC Stock Is Skyrocketing 104...

Seeking Alpha - 4 months ago

CTI BioPharma: A Nano Cap With Interesting Prospects

PRNewsWire - 7 months ago

SEATTLE, June 1, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hos...

PRNewsWire - 7 months ago

SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conf...

Seeking Alpha - 11 months ago

CTI Biopharma Accelerated Review, And Other News: The Good, Bad, And Ugly Of Biopharma

About CTIC

CTI BioPharma, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly kno... [Read more...]

Industry
Biotechnology
IPO Date
Mar 21, 1997
CEO
Adam Craig
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
CTIC
Full Company Profile

Financial Performance

In 2019, CTI BioPharma's revenue was $3.35 million, a decrease of -87.28% compared to the previous year's $26.29 million. Losses were -$40.02 million, 36.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CTI BioPharma stock is "Buy." The 12-month stock price forecast is 7.70, which is an increase of 135.47% from the latest price.

Price Target
$7.70
(135.47% upside)
Analyst Consensus: Buy